Once-daily elvitegravir matches raltegravir
HIV treatment in primary infection: 48 week course modestly delays CD4 drop
The roll-out of male circumcision: reduction in HIV prevalence, condom use maintained
Cognitive impairment still common but ART reduces risk
From 'what if' to 'what now': implementing the new prevention technologies
Maraviroc improves liver fibrosis in HIV/hepatitis C co-infected patients
We have the tools – now we need the money
Treatment as prevention: what are the next steps?
Small study shows women on stable HIV therapy have very low levels of HIV and high drug concentrations in genital fluids
